Prajna Guha, PhD

Publications

• Published on 7/22/2024

  Ghosh CC, Cournoyer L, Liu Y, Ballarin A, Layman IB, LaPorte J, Morrissey M, Fraser K, Perati S, Cox BF, Yakirevich E, Treaba DO, Murtha TD, Guha P, Katz SC, Davar D. Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases. J Immunother Cancer. 2024 Jul 22; 12(7). PMID: 39038918.

  Read at: PubMed
• Published on 6/15/2022

  Sullivan KM, Jiang X, Guha P, Lausted C, Carter JA, Hsu C, Labadie KP, Kohli K, Kenerson HL, Daniel SK, Yan X, Meng C, Abbasi A, Chan M, Seo YD, Park JO, Crispe IN, Yeung RS, Kim TS, Gujral TS, Tian Q, Katz SC, Pillarisetty VG. Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. Gut. 2023 Feb; 72(2):325-337. PMID: 35705369.

  Read at: PubMed
• Published on 6/14/2022

  Ghosh CC, Heatherton KR, Connell KPO, Alexander IS, Greer DA, LaPorte J, Guha P, Cox BF, Katz SC. Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition. Cancer Gene Ther. 2022 Dec; 29(12):1854-1865. PMID: 35697801.

  Read at: PubMed
• Published on 3/11/2022

  Guha P, Heatherton KR, O'Connell KP, Alexander IS, Katz SC. Assessing the Future of Solid Tumor Immunotherapy. Biomedicines. 2022 Mar 11; 10(3). PMID: 35327456.

  Read at: PubMed
• Published on 12/17/2021

  Chai LF, Hardaway JC, Heatherton KR, O'Connell KP, LaPorte JP, Guha P, Lopes MC, Rabinowitz BA, Jaroch D, Cox BF, Knight R, Katz SC. Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis Model. J Surg Res. 2022 04; 272:37-50. PMID: 34929499.

  Read at: PubMed
• Published on 12/13/2021

  Guha P, Katz SC. Strategies for manufacturing cell therapy products aligned with patient needs. Methods Cell Biol. 2022; 167:203-226. PMID: 35152997.

  Read at: PubMed
• Published on 9/4/2021

  DaSilva NA, Barlock BJ, Guha P, Ghosh CC, Trebino CE, Camberg JL, Katz SC, Rowley DC. Proteomic signatures of myeloid derived suppressor cells from liver and lung metastases reveal functional divergence and potential therapeutic targets. Cell Death Discov. 2021 Sep 04; 7(1):232. PMID: 34482371.

  Read at: PubMed
• Published on 7/21/2021

  Chai LF, Hardaway JC, Heatherton KR, O'Connell KP, Lopes MC, Rabinowitz BA, Ghosh CC, Guha P, Jaroch D, Cox BF, Katz SC. Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity. Vaccines (Basel). 2021 Jul 21; 9(8). PMID: 34451932.

  Read at: PubMed
• Published on 11/23/2020

  Guha P, Gardell J, Rabinowitz B, Lopes M, DaSilva NA, Rowley D, Katz SC. Monocytic and granulocytic myeloid-derived suppressor cell plasticity and differentiation are organ-specific. Oncogene. 2021 01; 40(3):693-704. PMID: 33230244.

  Read at: PubMed
• Published on 8/1/2020

  Katz SC, Moody AE, Guha P, Hardaway JC, Prince E, LaPorte J, Stancu M, Slansky JE, Jordan KR, Schulick RD, Knight R, Saied A, Armenio V, Junghans RP. HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery. J Immunother Cancer. 2020 08; 8(2). PMID: 32843493.

  Read at: PubMed

View 7 more publications: View full profile at BUMC